The Hong Kong Society of Uro-oncology (HKSUO) was founded four years ago as a platform for multi-speciality discussion and collaboration on urological cancers. During this time the society has played an important role locally in advancing understanding of the latests advances in the man-agement and treatment of the disease, and in the promotion of cutting edge applications and treatments.
This year at the HKSUO Fourth Annual Scientific Meeting we continue this thread but at a regional level. We are very pleased to welcome several world class guest speakers from across the globe to share with us their research and experiences. The speakers will be covering advances in the management of urological cancers, with a focus on the continuing evolution and developments in immuno-therapy and other forms of target therapy.
The meeting will also look at the future direction of research in new and explorative combination therapies in new clinical settings, and in particular advances in the use of bio-markers to predict the response of immune-agents. The potential to push for earlier clinical intervention, achieve precision medicine and highly personalised treatments remains an exciting prospect.
Significant advances continue to be made each year, and with each step forward new and exciting opportunities present themselves. Now more than ever, to provide the best we can to patients, we need to stay at the forefront of medicine.
The HKSUO continues to grow as an organisation. Our diverse membership, that includes a diverse range of specialist professionals, including clinical researchers, practicing doctors, nurses, and other medical practitioners, makes us uniquely able to facilitate cross-disciplinary understanding and collaboration.
It is only with your support has the HKSUO been able to achieve its goals, to continue hosting our Scientific Meetings and to look forward to expanding as a regional platform. Thank you again for supporting us, and we look forward to seeing you at our keynote event.
of the coming meeting
Advances in diagnosis and imaging of prostate cancer |
Management of M0 CRPC |
Updates in mHSPC |
Novel therapy for prostate cancer |
Oligometastasis in prostate cancer |
Advances in mRCC management |
Systemic therapy in NMIBC |
Targeted therapy in urothelial carcinoma |









United States